65,437 trials
Type 2 Diabetes
Primary: Mean Change in HbA1c (Per Protocol) — -0.96; -1.04; -0.82 percent change
Diabetes Mellitus, Type 2 · End-Stage Kidney Disease
Primary: Change From Baseline in Hemoglobin A1c After Sitagliptin Treatment — 7.89; 7.15; -0.74 Percent hemoglobin A1c — p=<0.001
Sickle Cell Anemia
Primary: Percentage of Participants With Hemorrhagic Events Requiring Medical Intervention During the Treatment Duration — 0; 0 percentage of participants
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Qualitative Amyloid Image Assessment — 34; 23; 11; 11 participants — p=0.0002
Intubation; Difficult
Primary: Number of the Patients With Successful Nasotracheal Intubation — 35; 18 participants
Hypertension
Primary: Percentage of Patients With Blood Pressure < 140/90 mm Hg — 69.6 Percentage of participants
Leukemia
Primary: Number of Participants (With Increase) Immune Response to GM-CSF With a Pneumococcal Vaccine — 0; 0; 1; 1 participants
Paget's Disease of Bone
Primary: Number of Patients Who Had Therapeutic Response at 6 Months — 84; 67 participants
Anemia, Aplastic · Amegakaryocytic Thrombocytopenia · Diamond-Blackfan Anemia
Primary: Treatment Failures
Sore Throat · Pain
Primary: Subjects Assessment of Sore Throat Pain at 24 Hours — 4; 4; 5 units on a scale (1 to 5) — p=<0.001
Alzheimer's Disease
Primary: Mean Cortical to Cerebellum SUVR — 1.416; 1.005; 1.407; 1.007 SUVR
Congenital Heart Disease
Primary: To Evaluate the Incidence of the Pre-proendothelin SNP at Nucleotide 5665 — 10 participants
Breast Cancer
Primary: FFDM (Full Field Digital Mammography) Mammogram Scores — 12; 0 FFDM Mammogram set
Urgency Frequency · Urinary Urge Incontinence
Primary: Number of Urinary Incontinent Episodes Per Day — 3.83; 2.37; 2.82 Episodes Per Day — p=0.008
Bone Marrow Transplantation · Distress
Primary: Number of Days With Pain Scores >3 Measured on Numeric Rating Scale (Range 0-10; 0 for no Pain; 10 for Worst Pain Imaginable) — 7.7; 8.3 days — p=0.80